NDATOPICALSOLUTION
Approved
Dec 1985
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
EXIDINE (chlorhexidine gluconate) by Johnson & Johnson is clinical pharmacology periogard® (chlorhexidine gluconate oral rinse usp, 0. First approved in 1985.
Drug data last refreshed 48m ago · AI intelligence enriched 6h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EXIDINE (Chlorhexidine Gluconate 0.12%) is a topical oral rinse solution that provides broad-spectrum antimicrobial activity against aerobic and anaerobic oral bacteria. It works by reducing bacterial plaque counts by 54-97% through direct antimicrobial action in the oral cavity, with retained drug slowly released into oral fluids. Indicated for oral hygiene in patients at risk for or with plaque-related oral disease.
LOE Approaching
Product is in late lifecycle stage with moderate competitive pressure (30%), indicating limited growth opportunities and likely consolidating commercial team size.
Mechanism of Action
CLINICAL PHARMACOLOGY PerioGard® (Chlorhexidine Gluconate Oral Rinse USP, 0.12%) provides antimicrobial activity during oral rinsing. The clinical significance of chlorhexidine gluconate oral rinse's antimicrobial activities is not clear. Microbiological sampling of plaque has shown a general…
Indications
Worked on EXIDINE at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.